Julie R. Brahmer, MD

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.

Julie Renee Brahmer, MD, MSc, discusses upcoming and recent trials that may change the sequencing of targeted therapies in patients with locally advanced non–small cell lung cancer.

Julie R. Brahmer, MD, discusses the circumstances in which a physician can choose osimertinib over other EGFR tyrosine kinase inhibitors for patients with&nbsp;<em>EGFR</em>-mutant lung cancer.

Julie R. Brahmer, MD, discusses the role of molecular testing for patients with lung cancer and why this is particularly important for those with early-stage disease.

Although immune checkpoint inhibitor therapy has represented a paradigm shift in the treatment of multiple types of cancer, many patients&rsquo; cancers do not respond at all to these therapies or develop resistance after an initial period of response, according to Julie R. Brahmer, MD.&nbsp;

Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.

Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non&ndash;small cell lung cancer. Durvalumab was recently approved by the FDA as a consolidation therapy for patients with stage III&nbsp;locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, reviews developments in 2017 for the treatment of lung cancer.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab (Opdivo) in previously treated advanced non-small cell lung cancer (NSCLC).

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

Julie R. Brahmer, MD, explains the role of the PD-1 pathway and the ligands PD-L1 and PD-L2 in the regulation of the immune system.

Julie R. Brahmer, MD, discusses tumor vaccines for patients with lung cancer.

Julie R. Brahmer, MD, Associate Professor, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses patient response to immunotherapy.